(VIANEWS) - Oportun Financial Corporation (OPRT), MasTec (MTZ), Pacira BioSciences (PCRX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Oportun Financial Corporation (OPRT)
28.1% sales growth and 8.66% return on equity
Oportun Financial Corporation provides financial services in the United States.
Oportun Financial Corporation's sales growth this year is anticipated to be 5.7% and 31.3% for next year.
Year-on-year quarterly revenue growth grew by 20.4%, now sitting on 523.75M for the twelve trailing months.
Volume
Today's last reported volume for Oportun Financial Corporation is 93306 which is 15.95% below its average volume of 111021.
Oportun Financial Corporation's sales growth for the next quarter is 28.1%. The company's growth estimates for the present quarter and the next is 16.7% and 12.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.66%.
Volatility
Oportun Financial Corporation's last day, last week, and last month's current intraday variation average was 2.63%, 3.12%, and 2.74%, respectively.
Oportun Financial Corporation's highest amplitude of average volatility was 8.25% (day), 6.80% (last week), and 5.94% (last month), respectively.
Oportun Financial Corporation's Stock Yearly Top and Bottom Value
Oportun Financial Corporation's stock is valued at $21.28 at 05:22 EST, way below its 52-week high of $27.95 and way above its 52-week low of $15.35.
Oportun Financial Corporation's Moving Average
Oportun Financial Corporation's worth is way below its 50-day moving average of $24.18 and below its 200-day moving average of $22.21.2. MasTec (MTZ)
27.7% sales growth and 17.68% return on equity
MasTec, Inc., an infrastructure construction company, provides engineering, building, installation, maintenance, and upgrade services for communications, energy, utility, and other infrastructure primarily in the United States and Canada.
MasTec's sales growth this year is expected to be 28.7% and 9.7% for next year.
Year-on-year quarterly revenue growth grew by 41.6%, now sitting on 7.78B for the twelve trailing months.
Volume
Today's last reported volume for MasTec is 302264 which is 55.44% below its average volume of 678422.
MasTec's sales growth is a negative 0% for the ongoing quarter and 27.7% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 7.7% and negative -24%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.68%.
Volatility
MasTec's last day, last week, and last month's current intraday variation average was 1.00%, 1.53%, and 2.45%, respectively.
MasTec's highest amplitude of average volatility was 3.41% (day), 3.16% (last week), and 3.89% (last month), respectively.
MasTec's Stock Yearly Top and Bottom Value
MasTec's stock is valued at $87.98 at 05:22 EST, way under its 52-week high of $122.33 and way higher than its 52-week low of $65.18.
MasTec's Moving Average
MasTec's value is under its 50-day moving average of $91.78 and way under its 200-day moving average of $98.06.3. Pacira BioSciences (PCRX)
15.5% sales growth and 32.38% return on equity
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States.
Pacira BioSciences's sales growth this year is expected to be 27.2% and 15.7% for next year.
Year-on-year quarterly revenue growth grew by 79.6%, now sitting on 503.08M for the twelve trailing months.
Volume
Today's last reported volume for Pacira BioSciences is 549719 which is 14.12% above its average volume of 481690.
Pacira BioSciences's sales growth for the next quarter is 15.5%. The company's growth estimates for the current quarter and the next is 14.7% and 5.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.38%.
Volatility
Pacira BioSciences's last day, last week, and last month's current intraday variation average was 2.32%, 1.68%, and 1.49%, respectively.
Pacira BioSciences's highest amplitude of average volatility was 5.43% (day), 4.59% (last week), and 3.80% (last month), respectively.
Pacira BioSciences's Stock Yearly Top and Bottom Value
Pacira BioSciences's stock is valued at $52.53 at 05:22 EST, way below its 52-week high of $80.00 and way above its 52-week low of $45.05.
Pacira BioSciences's Moving Average
Pacira BioSciences's worth is under its 50-day moving average of $54.03 and way under its 200-day moving average of $60.48.4. Ralph Lauren Corporation (RL)
9.8% sales growth and 14.93% return on equity
Ralph Lauren Corporation designs, markets, and distributes lifestyle products in North America, Europe, Asia, and internationally.
Ralph Lauren Corporation's sales growth this year is expected to be 35.1% and 4.2% for next year.
Year-on-year quarterly revenue growth grew by 26%, now sitting on 5.6B for the twelve trailing months.
Volume
Today's last reported volume for Ralph Lauren Corporation is 885102 which is 2.02% below its average volume of 903393.
Ralph Lauren Corporation's sales growth is a negative 0% for the ongoing quarter and 9.8% for the next. The company's growth estimates for the ongoing quarter and the next is 30.5% and negative -26.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.93%.
Volatility
Ralph Lauren Corporation's last day, last week, and last month's current intraday variation average was 0.55%, 1.56%, and 1.88%, respectively.
Ralph Lauren Corporation's highest amplitude of average volatility was 4.64% (day), 4.51% (last week), and 3.77% (last month), respectively.
Ralph Lauren Corporation's Stock Yearly Top and Bottom Value
Ralph Lauren Corporation's stock is valued at $115.05 at 05:22 EST, way below its 52-week high of $142.06 and way above its 52-week low of $98.33.